Vaidya Sane

how big is Vaidya Sane?

As of Jun 06, Vaidya Sane Ayurved Laboratories Ltd has a market capitalization of 160.00 Cr, classifying it as a Micro Cap company, with consolidated net sales of 19585.66 Cr and net profit of 1448.51 Cr over the latest four quarters.

Market Cap: <BR>As of Jun 06, Vaidya Sane Ayurved Laboratories Ltd has a market capitalization of 160.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, the sum of Net Sales is 19585.66 Cr and the sum of Net Profit is 1448.51 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: <BR>This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 55.60 Cr, and the Total Assets amount to 70.82 Cr.

What does Vaidya Sane do?

Vaidya Sane Ayurved Laboratories Ltd is a micro-cap company in the hospital industry, reporting net sales of ₹5,110 Cr and a net profit of ₹235 Cr for September 2023. Key metrics include a P/E ratio of 28.00 and a return on equity of 13.84%.

Overview:<BR>Vaidya Sane Ayurved Laboratories Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated in 1999 as a Private Limited Company and later converted into a Public Limited Company. The latest quarterly results reported net sales and profit for September 2023.<BR><BR>Financial Snapshot:<BR>Net Sales: 5,110 Cr (Quarterly Results - Sep 2023) <BR>Net Profit: 235 Cr (Quarterly Results - Sep 2023) <BR>Market-cap: Rs 160 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00 <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.40 <BR>Return on Equity: 13.84% <BR>Price to Book: 3.86 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

When is the next results date for Vaidya Sane?

No Upcoming Board Meetings

Has Vaidya Sane declared dividend?

Yes, Vaidya Sane Ayurved Laboratories Ltd has declared a 2% dividend, amounting to ₹0.20 per share, with an ex-date of September 5, 2023. However, total returns over various periods have shown negative performance, with minimal contributions from dividends.

Yes, Vaidya Sane Ayurved Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: ₹0.20<BR>- Ex-date: 05 Sep 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -3.24%, the dividend return was 0%, resulting in a total return of -3.24%.<BR><BR>Over the past year, the price return was -1.3%, the dividend return was 0%, leading to a total return of -1.3%.<BR><BR>In the 2-year period, the price return was -41.09%, the dividend return was 0.08%, resulting in a total return of -41.01%.<BR><BR>For the 3-year period, the price return was -18.02%, the dividend return was 0.26%, which led to a total return of -17.76%.<BR><BR>In the 4-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>Over the last 5 years, both the price return and dividend return were 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Vaidya Sane has declared a dividend, the total returns over various periods indicate a trend of negative performance, particularly in the longer term, with minimal contributions from dividends.

Who are the peers of the Vaidya Sane?

Vaidya Sane's peers include Max Healthcare, Apollo Hospitals, Fortis Health, and others. Management risk varies from excellent to below average, with Fortis Health showing the highest 1-year return at 59.65%, while Vaidya Sane, Sangani Hospital, and Aatmaj Health have a return of 0.00%.

Peers: The peers of Vaidya Sane are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Lotus Eye Hospit, Fortis Malar, Shanmuga Hos., Sangani Hospital, and Aatmaj Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Narayana Hrudaya, Global Health, Shanmuga Hos., and Aatmaj Health, while Good management risk is found at Apollo Hospitals and the rest. Average management risk is noted at Fortis Health., Lotus Eye Hospit, and Sangani Hospital, while Below Average management risk is seen at Fortis Malar. Growth is Excellent at Max Healthcare and Apollo Hospitals, Good at Fortis Health., Narayana Hrudaya, and Vaidya Sane, while Average growth is noted at Global Health, and Below Average growth is observed at Lotus Eye Hospit, Shanmuga Hos., Fortis Malar, Sangani Hospital, and Aatmaj Health. Capital Structure is Excellent at Max Healthcare and Shanmuga Hos., Good at Fortis Health., Narayana Hrudaya, Global Health, and Aatmaj Health, while Average is seen at Apollo Hospitals and Lotus Eye Hospit, and Below Average at Fortis Malar.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fortis Health. at 59.65%, while the lowest is Sangani Hospital and Aatmaj Health, both at 0.00%. Vaidya Sane's 1-year return is also 0.00%, which is the same as Sangani Hospital and Aatmaj Health. Additionally, Global Health and Lotus Eye Hospit have negative six-month returns.

What is the technical trend for Vaidya Sane?

As of June 3, 2025, the market trend is mildly bullish, supported by a bullish weekly MACD and Bollinger Bands, although caution is advised due to mixed signals from the monthly MACD and daily moving averages.

As of 3 June 2025, the technical trend has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive outlook, while the monthly MACD is mildly bearish, indicating some caution. The Bollinger Bands on the weekly are bullish, reinforcing the upward momentum. However, the daily moving averages are mildly bearish, suggesting short-term weakness. The Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames, and the On-Balance Volume (OBV) is also mildly bullish, reflecting positive accumulation. Overall, the current stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some mixed signals from other indicators.

Who are in the management team of Vaidya Sane?

As of March 2022, the management team of Vaidya Sane includes Rohit Madhav Sane (Managing Director & CEO), Vidyut Bipin Ghag (Whole-time Director), and four Independent Directors: Ratnakar Venkappa Rai, Sushrut Raghavendra Dambal, Mahesh P. Kshirsagar, along with Abhishek Ajay Deshpande (Company Secretary & Compliance Officer).

As of March 2022, the management team of Vaidya Sane includes the following individuals:<BR><BR>1. Rohit Madhav Sane - Managing Director & CEO<BR>2. Vidyut Bipin Ghag - Whole-time Director<BR>3. Ratnakar Venkappa Rai - Independent Director<BR>4. Sushrut Raghavendra Dambal - Independent Director<BR>5. Mahesh P. Kshirsagar - Independent Director<BR>6. Abhishek Ajay Deshpande - Company Secretary & Compliance Officer<BR><BR>These members play key roles in the governance and operational management of the company.

Who are the top shareholders of the Vaidya Sane?

The top shareholders of Vaidya Sane are led by promoter Rohit Madhav Sane, who holds 66.29% of the shares, followed by public shareholder Virtuous Capital Limited with 4.17%. Individual investors own 21.94%, with no mutual funds or foreign institutional investors currently involved.

The top shareholders of Vaidya Sane include the promoters, with Rohit Madhav Sane holding the largest share at 66.29%. The highest public shareholder is Virtuous Capital Limited, which holds 4.17%. Additionally, individual investors collectively own 21.94% of the company. Notably, there are no mutual funds or foreign institutional investors currently holding shares in Vaidya Sane.

How has been the historical performance of Vaidya Sane?

Vaidya Sane has shown significant growth from Mar'22 to Mar'25, with net sales rising to 89.85 Cr despite a decline from the previous year, and profit before tax increasing to 9.90 Cr. The company improved its operating profit and earnings per share, indicating a strong upward trend in revenue and profitability.

Answer:<BR>The historical performance of Vaidya Sane shows a significant growth trajectory, particularly from fiscal year Mar'22 to Mar'25.<BR><BR>Breakdown:<BR>Vaidya Sane's net sales increased from zero in Mar'22 to 89.85 Cr in Mar'25, although there was a decline from 99.33 Cr in Mar'24. Total operating income followed a similar trend, rising from zero to 89.85 Cr, with a slight decrease from the previous year. The company managed to reduce its total expenditure from 94.83 Cr in Mar'24 to 76.34 Cr in Mar'25, contributing to an operating profit (PBDIT) of 15.37 Cr in Mar'25, up from 6.25 Cr in Mar'24. Profit before tax also saw a notable increase, reaching 9.90 Cr in Mar'25 compared to 2.86 Cr in Mar'24, while profit after tax rose to 7.15 Cr from 1.99 Cr. The earnings per share (EPS) improved significantly from 1.88 in Mar'24 to 6.79 in Mar'25. On the balance sheet, total liabilities increased from 54.81 Cr in Mar'23 to 70.82 Cr in Mar'24, with total assets also rising to 70.82 Cr in Mar'24. Cash flow from financing activities showed a strong inflow of 14.00 Cr in Mar'24, contributing to a closing cash balance of 13.00 Cr, up from 1.00 Cr in the previous year. Overall, Vaidya Sane has demonstrated a robust growth pattern in revenue and profitability over the past few years.

Is Vaidya Sane overvalued or undervalued?

As of November 6, 2025, Vaidya Sane is considered very expensive and overvalued with a PE ratio of 48.20 and an EV to EBITDA of 26.00, significantly higher than its peers like Sun Pharma and Cipla, despite a strong year-to-date return of 90.47%.

As of 6 November 2025, the valuation grade for Vaidya Sane has moved from expensive to very expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 48.20, an EV to EBITDA of 26.00, and a PEG ratio of 0.11, which indicates a significant premium compared to its peers.<BR><BR>In comparison to its industry peers, Sun Pharma has a PE ratio of 35.02 and an EV to EBITDA of 10.54, while Cipla is valued more attractively with a PE ratio of 22.27 and an EV to EBITDA of 5.53. Despite Vaidya Sane's strong year-to-date return of 90.47%, which outperforms the Sensex's 7.89%, the current valuation metrics suggest that the stock is not justified at its price level.

Should I buy, sell or hold Vaidya Sane Ayurved Laboratories Ltd?

Why is Vaidya Sane Ayurved Laboratories Ltd falling/rising?

As of 17-Mar, Vaidya Sane Ayurved Laboratories Ltd's stock price is at 206.25, reflecting a year-to-date decline of 27.52%. The stock is underperforming its sector and moving averages, with recent financial results indicating a concerning reliance on non-operating income.

As of 17-Mar, Vaidya Sane Ayurved Laboratories Ltd's stock price is falling, currently at 206.25, reflecting a decrease of 0.15 (-0.07%). This decline is part of a broader trend, as the stock has underperformed the market, with a year-to-date drop of 27.52% compared to the Sensex's decline of 9.75%. <BR><BR>Today's performance indicates that the stock has underperformed its sector by 0.35%. Additionally, it is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a consistent downward trend in its price. Despite a significant increase in delivery volume, which rose by 996.15% against the 5-day average, the overall sentiment appears negative.<BR><BR>The company's recent financial results show flat performance in September 2023, with a concerning reliance on non-operating income, which constituted 40.34% of profit before tax. This factor, combined with the stock's recent performance metrics, contributes to the perception that it may not be a favorable investment at this time, leading to its current decline in stock price.

Why is Vaidya Sane Ayurved Laboratories Ltd falling/rising?

As of 18-Mar, Vaidya Sane Ayurved Laboratories Ltd's stock price is at 205.60, reflecting a bearish trend with significant underperformance and decreased investor interest. Despite strong long-term growth, recent operational concerns and a substantial decline in delivery volume contribute to the stock's current downward pressure.

As of 18-Mar, Vaidya Sane Ayurved Laboratories Ltd's stock price is falling, currently at 205.60, reflecting a decrease of 0.65 or 0.32%. This decline is evident in its performance metrics, as the stock has underperformed the sector by 0.59% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>Additionally, investor participation has significantly decreased, with delivery volume dropping by 80.89% compared to the 5-day average, suggesting a lack of interest from investors. The stock has also shown poor performance over various time frames, including a year-to-date decline of 27.75%, compared to a 9.00% drop in the benchmark index, Sensex. <BR><BR>While the company has demonstrated strong long-term growth with an annual operating profit increase of 47.54% and a remarkable 130.75% return over the past year, the recent flat results in September 2023, where non-operating income constituted 40.34% of profit before tax, raise concerns about its operational efficiency. These factors combined contribute to the current downward pressure on the stock price.

Why is Vaidya Sane Ayurved Laboratories Ltd falling/rising?

As of 19-Mar, Vaidya Sane Ayurved Laboratories Ltd's stock price is at 195.00, down 5.16%. The decline is due to underperformance compared to the Sensex, trading below key moving averages, and decreased investor interest, despite some positive financial metrics.

As of 19-Mar, Vaidya Sane Ayurved Laboratories Ltd's stock price is falling, currently at 195.00, reflecting a decrease of 10.6 points or 5.16%. This decline can be attributed to several factors highlighted in the provided data. <BR><BR>Over the past week, the stock has underperformed with a loss of 5.57%, while the benchmark Sensex has only declined by 2.69%. The one-month performance shows a more significant drop of 13.33% for the stock compared to a 9.63% decrease in the Sensex. Year-to-date, the stock has fallen by 31.47%, contrasting sharply with the Sensex's decline of 11.97%. <BR><BR>Today's performance indicates that the stock has underperformed its sector by 3.01%. Additionally, it is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, suggesting a bearish trend. Investor participation has also decreased, with a delivery volume drop of 42.03% compared to the 5-day average, indicating reduced interest in trading the stock.<BR><BR>Despite some positive aspects, such as a low debt-to-equity ratio and healthy long-term growth in operating profit, the company's recent flat results and reliance on non-operating income, which constitutes 40.34% of profit before tax, may be contributing to investor concerns. Overall, these factors collectively explain the current downward movement in the stock price of Vaidya Sane Ayurved Laboratories Ltd.

Why is Vaidya Sane Ayurved Laboratories Ltd falling/rising?

As of 20-Mar, Vaidya Sane Ayurved Laboratories Ltd's stock price has risen to 201.00, reflecting a 3.08% increase, driven by a strong annual return of 99.01%. However, concerns include trading below moving averages, declining investor participation, and flat results in September 2023, despite the company's low debt and healthy long-term growth.

As of 20-Mar, Vaidya Sane Ayurved Laboratories Ltd is experiencing a rise in its stock price, currently at 201.00, reflecting an increase of 6.0 or 3.08%. This upward movement can be attributed to its strong performance over the past year, where the stock has generated a remarkable return of 99.01%, significantly outperforming the broader market, which has seen a return of only 0.76%. <BR><BR>Despite this positive long-term growth, there are some concerning indicators. The stock has been trading below its moving averages across various time frames, indicating a potential weakness in momentum. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 74.64% compared to the 5-day average. <BR><BR>While the company maintains a low debt-to-equity ratio and has shown healthy long-term growth in operating profit, the recent flat results in September 2023, particularly the high proportion of non-operating income contributing to profit before tax, may raise concerns among investors. Nonetheless, the current rise in stock price suggests that positive sentiment from its past performance is outweighing these negative factors at this time.

Why is Vaidya Sane Ayurved Laboratories Ltd falling/rising?

As of 23-Mar, the stock price of Vaidya Sane Ayurved Laboratories Ltd is at 201.00, unchanged from the previous session, with a month decline of 10.65% and a year-to-date drop of 29.36%. Despite a strong annual rise of 91.61%, current trends show a bearish outlook due to declining performance and reduced investor interest.

As of 23-Mar, the stock price of Vaidya Sane Ayurved Laboratories Ltd is currently at 201.00, showing no change from the previous trading session. The stock has experienced a decline of 10.65% over the past month and a significant year-to-date drop of 29.36%. Despite a strong performance over the past year, where it has risen by 91.61%, recent trends indicate a concerning downturn.<BR><BR>The stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 82.64% compared to the 5-day average, indicating reduced interest from investors.<BR><BR>While the company has a low debt-to-equity ratio and has shown healthy long-term growth in operating profit, the flat results reported in September 2023, particularly the fact that non-operating income constituted 40.34% of profit before tax, raise concerns about the sustainability of its earnings. This combination of declining stock performance, reduced trading activity, and mixed financial results contributes to the stock's current stagnation and potential downward pressure.

Why is Vaidya Sane Ayurved Laboratories Ltd falling/rising?

As of 24-Mar, Vaidya Sane Ayurved Laboratories Ltd's stock price is at 195.00, down 2.99%, with significant declines over various periods and underperformance compared to its sector. Concerns about the sustainability of earnings, primarily driven by non-operating income, contribute to the bearish trend.

As of 24-Mar, Vaidya Sane Ayurved Laboratories Ltd's stock price is falling, currently at 195.00, which reflects a decrease of 6.0 or 2.99%. This decline is evident in the stock's performance over various periods, showing a 1-week drop of 5.45% and a 1-month decrease of 6.94%. Year-to-date, the stock has fallen significantly by 31.47%, while the broader market, represented by the Sensex, has only declined by 12.31% during the same period.<BR><BR>Today's trading performance indicates that the stock has underperformed its sector by 4.11%. Additionally, Vaidya Sane is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, suggesting a bearish trend. The delivery volume has also seen a drastic decline, with a reported drop of 82.64% against the 5-day average, indicating reduced investor participation and interest.<BR><BR>While the company has shown strong long-term growth with an annual operating profit increase of 47.54% and has generated impressive returns of 86.25% over the past year, recent results have been flat, particularly with a significant portion of profit before tax (40.34%) coming from non-operating income. This raises concerns about the sustainability of its earnings, contributing to the current downward pressure on the stock price.

Why is Vaidya Sane Ayurved Laboratories Ltd falling/rising?

As of 25-Mar, Vaidya Sane Ayurved Laboratories Ltd's stock price is at 185.00, reflecting a 5.13% decline. The stock has significantly underperformed year-to-date, dropping 34.99%, and is trading below all key moving averages, indicating a consistent downward trend.

As of 25-Mar, Vaidya Sane Ayurved Laboratories Ltd's stock price is falling, currently at 185.00, which reflects a decrease of 10.0 or 5.13%. This decline is evident in the stock's performance over various periods, with a 1-week drop of 10.02% and a 1-month decrease of 15.12%. Year-to-date, the stock has fallen by 34.99%, significantly underperforming compared to the Sensex, which has only declined by 10.80% in the same timeframe.<BR><BR>Today's trading performance indicates that the stock has underperformed its sector by 7.02%. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a consistent downward trend. Investor participation has also decreased, with delivery volume on 24 March falling by 93.24% compared to the 5-day average, indicating reduced interest from investors.<BR><BR>While the company has shown strong long-term growth with an annual operating profit increase of 47.54% and has historically provided substantial returns over the past year (84.63%), recent results have been flat, particularly in September 2023, where non-operating income constituted 40.34% of profit before tax. This reliance on non-operating income may raise concerns about the sustainability of the company's profitability, contributing to the stock's current decline.

Which are the latest news on Vaidya Sane?